Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nanobiotix Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:05.072 Good afternoon and good morning, and welcome to the Nanobiotics Conference call to discuss 00:00:05.072 -- 00:00:09.996 updates to our NBTX R3 development plan and our first quarter. 00:00:09.996 -- 00:00:15.279 Joining me on the call today are Laurent Levy, co-founder and chief executive officer, 00:00:15.279 -- 00:00:20.563 and Bart Van Ryn, chief financial officer, who will be available during the Q&A section. 00:00:20.563 -- 00:00:24.826 As a reminder, today's call is being webcast and will be available on our website for 00:00:24.826 -- 00:00:26.427 replay. 00:00:26.427 -- 00:00:30.798 I would like to remind you that this call will include forward-looking statements, which 00:00:30.798 -- 00:00:36.000 may include statements regarding the progress, success, and timing of our ongoing 00:00:36.000 -- 00:00:41.242 and planned clinical trials, collaborations, regulatory filings, 00:00:41.242 -- 00:00:46.264 dates of presentation, and future research and development efforts among 00:00:46.264 -- 00:00:47.985 other things. 00:00:47.985 -- 00:00:53.087 These forward-looking statements are based on current information, assumptions, and 00:00:53.087 -- 00:00:58.269 expectations that are subject to change. They are subject to significant risks 00:00:58.269 -- 00:01:03.480 and uncertainties that could cause the company's actual results to differ materially 00:01:03.480 -- 00:01:06.142 from our current expectations. 00:01:06.142 -- 00:01:11.746 Accordingly, you are cautioned not to place undue reliance on forward-looking statements. 00:01:11.746 -- 00:01:16.590 Please review the full description of risk factors that can be found in the documents 00:01:16.590 -- 00:01:21.614 we filed with the AMF in France and SEC in the United States, whic...